Dr Richard Hausmann resigns as President and CEO of Elekta

STOCKHOLM, June 2, 2020 – Elekta (EKTA-B.ST) announced today that Richard Hausmann, President and Chief Executive Officer, has decided to resign for personal reasons with immediate effect. Elekta’s Board of Directors has initiated a recruitment process and has appointed Gustaf Salford as Acting President and CEO effective from today.

Dr Laurent Leksell, Chairman of the Board, said: “We are grateful for Richard’s contributions to Elekta over the past four years. He has successfully driven, among other things, our strategic innovation agenda supporting our future growth, including the introduction of our breakthrough clinical solution, Unity. We acknowledge Richard’s desire to resign from Elekta, we sincerely thank him for his contributions and wish him all the best for the future.”

“It has been a privilege to lead Elekta’s journey over the past four years, helping our customers to improve the life of millions of cancer patients around the world. I am proud to have been part of driving Elekta forward to revolutionize cancer care. I wish Elekta and all its employees every success in the coming years. I now look forward to pursuing my interests and other things in life,” said Richard Hausmann.

Gustaf Salford has held senior management positions in Elekta for eleven years and, until today, the position as Executive Vice President and Chief Financial Officer. Johan Adebäck, Group Treasurer, with more than 15 years’ experience from senior Finance management positions in Elekta, has been appointed Acting Chief Financial Officer.

 

# # #

For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time

Mattias Thorsson, Head of Corporate Communications and Public Affairs
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 20:00 CET on June 2, 2020. (REGMAR)
 

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 20:00 CET on June 2, 2020. (REGMAR)
Image

Downloads

PDF Version

For further information, please contact

Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25,
E-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time

Mattias Thorsson, Head of Corporate Communications and Public Affairs
Tel: +46 70 865 8012,
E-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time